Published • loading... • Updated
Zealand, Roche’s Obesity Drug Helps Patients Lose up to 9.2% Weight in Mid-Stage Trial
Petrelintide also lowered blood sugar levels by as much as 0.65%, while about 1.9% of patients stopped treatment because of gastrointestinal side effects.
Summary by WTVB
7 Articles
7 Articles
Zealand, Roche's obesity drug helps patients lose up to 9.2 ...
·London, United Kingdom
Read Full Article
Denmark's Zealand Pharma has presented positive results for its potential treatment of overweight and obesity with the amylin analogue petrelintide, which is being developed together with Switzerland's Roche, according to a press release.
Zealand Pharma has positive data with its potential treatment for overweight and obesity, Petrelintide. The Phase 2 study shows an average weight loss of 9.2 percent after 28 weeks, as well as a reduction in long-term blood sugar levels and a very low dropout rate.
Coverage Details
Total News Sources7
Leaning Left0Leaning Right1Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
